循環腫瘤細胞在非小細胞肺癌中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

李鐳 ¹ ^# , 朱盈盈 ¹ ^# , 劉丹 ¹ , 張立 ² ,  李為民 ¹

1. ;
2. ;

Corresponding?author：

李為民, Email: weimi003@yahoo.com

Keywords：

DOI：

10.7507/1671-6205.2016022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李鐳, 朱盈盈, 劉丹, 張立, 李為民. 循環腫瘤細胞在非小細胞肺癌中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2016, 15(1): 87-91. doi: 10.7507/1671-6205.2016022 Copy

1.	Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med, 2014, 2:107.
2.	Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection:clinical impact and future directions. Cancer Lett, 2007, 253:180-204.
3.	Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization:moving toward personalized medicine. Ann Transl Med, 2014, 2:108.
4.	Fusi A, Metcalf R, Krebs M, et al. Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr Treat Options Oncol, 2013, 14:610-622.
5.	Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res, 2011, 17:827-835.
6.	Yoon SO, Kim YT, Jung KC, et al. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer, 2011, 71:209-216.
7.	Adamczyk LA, Williams H, Frankow A, et al. Current understanding of circulating tumor cells-potential value in malignancies of the central nervous system. Front Neurol, 2015, 6:174.
8.	Sleijfer S, Gratama JW, Sieuwerts AM, et al. Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer, 2007, 43:2645-2650.
9.	Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine:dream or reality? Ann Oncol, 2014, 25:2304-2313.
10.	Khoja L, Lorigan P, Dive C, et al. Circulating tumour cells as tumour biomarkers in melanoma:detection methods and clinical relevance. Ann Oncol, 2015, 26:33-39.
11.	Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel), 2014, 6:323-332.
12.	Gertler R, Rosenberg R, Fuehrer K, et al. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res, 2003, 162:149-155.
13.	Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices, 2011, 13:203-213.
14.	Ma YC, Wang L, Yu FL. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology. Technol Cancer Res Treat, 2013, 12:295-309.
15.	Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res, 2011, 13:228.
16.	Han Y, Su C, Liu Z. Methods for detection of circulating cells in non-small cell lung cancer. Front Biosci (Landmark Ed), 2014, 19:896-903.
17.	Harouaka R, Kang Z, Zheng SY, et al. Circulating tumor cells:advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther, 2014, 141:209-221.
18.	Kuniyoshi RK, Gehrke FDe S, Alves BC, et al. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol, 2015, 36:8075-8083.
19.	Wang HY, Ahn S, Kim S, et al. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Int J Clin Oncol, 2015, 20:878-890.
20.	Marin-Aguilera M, Reig O, Lozano JJ, et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. Oncotarget, 2015, 6:10604-10616.
21.	Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res, 2007, 13:2023-2029.
22.	Lu Y, Liang H, Yu T, et al. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer, 2015, 121:3036-3045.
23.	Sequist LV, Nagrath S, Toner M, et al. The CTC-chip:an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol, 2009, 4:281-283.
24.	Mascalchi M, Falchini M, Maddau C, et al. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC. J Cancer Res Clin Oncol, 2016, 142:195-200.
25.	Muinelo-Romay L, Vieito M, Abalo A, et al. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment. Cancers (Basel), 2014, 6:153-165.
26.	Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 2011, 29:1556-1563.
27.	Chen X, Wang X, He H, et al. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One, 2015, 10:e0126276.
28.	Chen X, Zhou F, Li X, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J Thorac Oncol, 2015, 10:1163-1171.
29.	Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol, 2013, 6:697-702.
30.	Cheng M, Liu L, Yang HS, et al. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev, 2014, 15:6369-6374.
31.	Botting GM, Rastogi I, Chhabra G, et al. Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. PLoS One, 2015, 10:e0136155.
32.	Engel J, Richters A, Getlik M, et al. Targeting drug resistance in EGFR with covalent inhibitors:a structure-based design approach. J Med Chem, 2015, 58:6844-6863.
33.	Ishii H, Azuma K, Sakai K, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC:Correlation with paired tumor samples. Oncotarget, 2015, 6:30850-30858.
34.	Freidin MB, Freydina DV, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem, 2015, 61:1299-1304.
35.	Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol, 2013, 31:2273-2281.
36.	Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment. PLoS One, 2014, 9:e103883.
37.	Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res, 2012, 18:2391-2401.
38.	Warth A, Cortis J, Soltermann A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer:a critical reappraisal of its prognostic role. Br J Cancer, 2014, 111:1222-1229.
39.	Li L, Liu D, Qiu ZX, et al. The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer:a systematic review and meta-analysis. PLoS One, 2015, 10:e0116771.
40.	Qiu ZX, Zhang K, Qiu XS, et al. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer:a meta-analysis. PLoS One, 2013, 8:e81451.
41.	Lee HW, Lee EH, Lee JH, et al. Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8:3955-3962.
42.	Juan O, Vidal J, Gisbert R, et al. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol, 2014, 16:637-643.
43.	Li J, Shi SB, Shi WL, et al. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res, 2014, 163:27-35.
44.	Zhu WF, Li J, Yu LC, et al. Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumour Biol, 2014, 35:1211-1219.
45.	Dorner AJ, Badola S, Niu H. Characterization of circulating tumor DNA for genetic assessment of solid tumors. Clin Pharmacol Ther, 2015, 98:16-18.
46.	Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem, 2015, 61:112-123.
47.	Huang WL, Wei F, Wong DT, et al. The emergent landscape of detecting EGFR mutations using circulating tumor DNA in lung cancer. Biomed Res Int, 2015, 2015:340732.
48.	Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer, 2015, 136:2158-2165.

1. Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med, 2014, 2:107.
2. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection:clinical impact and future directions. Cancer Lett, 2007, 253:180-204.
3. Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization:moving toward personalized medicine. Ann Transl Med, 2014, 2:108.
4. Fusi A, Metcalf R, Krebs M, et al. Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr Treat Options Oncol, 2013, 14:610-622.
5. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res, 2011, 17:827-835.
6. Yoon SO, Kim YT, Jung KC, et al. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer, 2011, 71:209-216.
7. Adamczyk LA, Williams H, Frankow A, et al. Current understanding of circulating tumor cells-potential value in malignancies of the central nervous system. Front Neurol, 2015, 6:174.
8. Sleijfer S, Gratama JW, Sieuwerts AM, et al. Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer, 2007, 43:2645-2650.
9. Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine:dream or reality? Ann Oncol, 2014, 25:2304-2313.
10. Khoja L, Lorigan P, Dive C, et al. Circulating tumour cells as tumour biomarkers in melanoma:detection methods and clinical relevance. Ann Oncol, 2015, 26:33-39.
11. Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel), 2014, 6:323-332.
12. Gertler R, Rosenberg R, Fuehrer K, et al. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res, 2003, 162:149-155.
13. Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices, 2011, 13:203-213.
14. Ma YC, Wang L, Yu FL. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology. Technol Cancer Res Treat, 2013, 12:295-309.
15. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res, 2011, 13:228.
16. Han Y, Su C, Liu Z. Methods for detection of circulating cells in non-small cell lung cancer. Front Biosci (Landmark Ed), 2014, 19:896-903.
17. Harouaka R, Kang Z, Zheng SY, et al. Circulating tumor cells:advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther, 2014, 141:209-221.
18. Kuniyoshi RK, Gehrke FDe S, Alves BC, et al. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol, 2015, 36:8075-8083.
19. Wang HY, Ahn S, Kim S, et al. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Int J Clin Oncol, 2015, 20:878-890.
20. Marin-Aguilera M, Reig O, Lozano JJ, et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. Oncotarget, 2015, 6:10604-10616.
21. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res, 2007, 13:2023-2029.
22. Lu Y, Liang H, Yu T, et al. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer, 2015, 121:3036-3045.
23. Sequist LV, Nagrath S, Toner M, et al. The CTC-chip:an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol, 2009, 4:281-283.
24. Mascalchi M, Falchini M, Maddau C, et al. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC. J Cancer Res Clin Oncol, 2016, 142:195-200.
25. Muinelo-Romay L, Vieito M, Abalo A, et al. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment. Cancers (Basel), 2014, 6:153-165.
26. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 2011, 29:1556-1563.
27. Chen X, Wang X, He H, et al. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One, 2015, 10:e0126276.
28. Chen X, Zhou F, Li X, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J Thorac Oncol, 2015, 10:1163-1171.
29. Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol, 2013, 6:697-702.
30. Cheng M, Liu L, Yang HS, et al. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev, 2014, 15:6369-6374.
31. Botting GM, Rastogi I, Chhabra G, et al. Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. PLoS One, 2015, 10:e0136155.
32. Engel J, Richters A, Getlik M, et al. Targeting drug resistance in EGFR with covalent inhibitors:a structure-based design approach. J Med Chem, 2015, 58:6844-6863.
33. Ishii H, Azuma K, Sakai K, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC:Correlation with paired tumor samples. Oncotarget, 2015, 6:30850-30858.
34. Freidin MB, Freydina DV, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem, 2015, 61:1299-1304.
35. Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol, 2013, 31:2273-2281.
36. Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment. PLoS One, 2014, 9:e103883.
37. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res, 2012, 18:2391-2401.
38. Warth A, Cortis J, Soltermann A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer:a critical reappraisal of its prognostic role. Br J Cancer, 2014, 111:1222-1229.
39. Li L, Liu D, Qiu ZX, et al. The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer:a systematic review and meta-analysis. PLoS One, 2015, 10:e0116771.
40. Qiu ZX, Zhang K, Qiu XS, et al. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer:a meta-analysis. PLoS One, 2013, 8:e81451.
41. Lee HW, Lee EH, Lee JH, et al. Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8:3955-3962.
42. Juan O, Vidal J, Gisbert R, et al. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol, 2014, 16:637-643.
43. Li J, Shi SB, Shi WL, et al. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res, 2014, 163:27-35.
44. Zhu WF, Li J, Yu LC, et al. Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumour Biol, 2014, 35:1211-1219.
45. Dorner AJ, Badola S, Niu H. Characterization of circulating tumor DNA for genetic assessment of solid tumors. Clin Pharmacol Ther, 2015, 98:16-18.
46. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem, 2015, 61:112-123.
47. Huang WL, Wei F, Wong DT, et al. The emergent landscape of detecting EGFR mutations using circulating tumor DNA in lung cancer. Biomed Res Int, 2015, 2015:340732.
48. Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer, 2015, 136:2158-2165.

Previous Article
哮喘患者呼出氣一氧化氮和氣道高反應性的關系探究
Next Article
雙重氧化酶與呼吸系統關系的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

循環腫瘤細胞在非小細胞肺癌中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content